医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

UPL Announces Collaboration With Meiji for Exclusive Access to Flupyrimin Rice in Southeast Asia

2021年05月11日 PM01:54
このエントリーをはてなブックマークに追加


 

MUMBAI, India

UPL Ltd., a global provider of sustainable agriculture solutions, today announced that its subsidiary has entered into a license agreement with Japanese company, Meiji Seika Pharma Co., Ltd. for exclusive access to Flupyrimin for rice in Southeast Asia.

Under the license agreement, UPL will obtain exclusive rights to develop, register and commercialize formulations of Flupyrimin for foliar applications in rice in Southeast Asia, expanding the on-going collaboration between the two companies with this compound.

In addition to this latest arrangement, in 2018 UPL’s subsidiary and Meiji entered into an exclusive licensing agreement for UPL to commercialize formulations of Flupyrimin for applications in rice in India. Furthermore, in 2020, the two companies signed a long-term global commercial exclusive agreement, excluding Japan, South Korea and Taiwan and non-exclusive in China, to use Flupyrimin in seed treatment and in-furrow applications.

Flupyrimin, discovered by Meiji, is a patented active ingredient and the only AI in the new mode of action subgroup, Pyridylidenes, defined by IRAC in 2021. It is a novel insecticide with unique biological properties that, among other benefits, is effective against major rice pests, such as brown plant hopper and rice stem borer, including those populations resistant to existing insecticides.

Together, both companies will continue their contributions to the development of differentiated solutions based on Flupyrimin to address farmer pain points and improve their livelihoods.

“We are pleased to expand our relationship with Meiji regarding Flupyrimin in this mutually beneficial collaboration to provide growers in Southeast Asia access to this important AI. Our OpenAgTM Purpose opens the door to developing and expanding key relationships that create sustainable growth for all and ensure farmer resilience,” said Jai Shroff, CEO of UPL. “Meiji is an important partner to UPL, and we look forward to continuing our collaboration, creating a win, win.”

“The UPL agreement is a significant step forward towards providing growers with differentiated solutions that address their challenges in the field. We are excited to continue to strengthen our relationship with UPL to deliver this innovative and effective AI to farmers in Southeast Asia,” said Daikichiro Kobayashi, President and Representative Director

ABOUT UPL

UPL Ltd. (NSE: UPL & BSE: 512070) is a global provider of sustainable agriculture products & solutions, with annual revenue exceeding $5 billion. We are a purpose-led company. Through OpenAg, UPL is focused on facilitating progress for the entire agricultural value chain. We are building a network that redefines the way an entire industry thinks and works – open to fresh ideas, innovative ways and new answers as we strive towards our mission to make each food product more sustainable. As one of the largest agriculture solutions companies worldwide, our robust portfolio consists of biologicals and traditional crop protection solutions with over 13,600 registrations. We are present in over 130 countries, represented by more than 10,000 colleagues globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210510006058/en/

CONTACT

Radhika Arora

Head of Investor Relations

UPL Ltd.

Radhika.Arora@upl-ltd.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アジェンディアのマンマプリント検査、NSABP B-42試験で長期内分泌療法の利点を予測する能力を初めて示す
  • アマゾンと全米安全評議会が米国で最も多い労働災害の解決に向け、この種で初となる提携関係を構築
  • Celltrion announces positive top-line results from global Phase III trial of regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment
  •  全米で実施したNational Cardiogenic Shock Initiative(NSCI)試験の最終結果が、Impellaによる早期血行動態サポートの有効性を実証
  • Celltrion Healthcare presents the first real-world data for Truxima® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress